Geode Capital Management LLC Boosts Position in Codexis, Inc. (NASDAQ:CDXS)

Geode Capital Management LLC raised its position in Codexis, Inc. (NASDAQ:CDXS) by 0.7% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,644,039 shares of the biotechnology company’s stock after acquiring an additional 11,082 shares during the quarter. Geode Capital Management LLC’s holdings in Codexis were worth $5,065,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Los Angeles Capital Management LLC bought a new position in shares of Codexis in the 2nd quarter worth approximately $54,000. Intech Investment Management LLC purchased a new stake in Codexis during the third quarter valued at approximately $66,000. Marshall Wace LLP bought a new position in Codexis in the second quarter worth approximately $89,000. Algert Global LLC boosted its stake in shares of Codexis by 17.1% during the 2nd quarter. Algert Global LLC now owns 41,556 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 6,069 shares during the last quarter. Finally, Squarepoint Ops LLC grew its position in shares of Codexis by 113.8% during the 2nd quarter. Squarepoint Ops LLC now owns 74,531 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 39,664 shares during the period. 78.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on CDXS. Benchmark reiterated a “hold” rating on shares of Codexis in a research report on Monday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 price objective on shares of Codexis in a research report on Friday, November 22nd.

Codexis Stock Up 8.6 %

Shares of CDXS opened at $5.43 on Friday. The business’s 50 day moving average is $4.56 and its 200 day moving average is $3.61. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. Codexis, Inc. has a 12-month low of $2.53 and a 12-month high of $6.08. The company has a market capitalization of $441.88 million, a PE ratio of -6.24 and a beta of 2.15.

Codexis (NASDAQ:CDXS) last released its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.04). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The company had revenue of $12.83 million for the quarter, compared to the consensus estimate of $11.64 million. During the same quarter in the previous year, the business earned ($0.26) EPS. Research analysts expect that Codexis, Inc. will post -0.77 earnings per share for the current fiscal year.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.